Grade 4 Upper Gastrointestinal Hemorrhage, CTCAE

MedGen UID:: 1635898
•Concept ID:: C4686986
•: Finding

Definition

Life-threatening consequences; urgent intervention indicated [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVGrade 4 Upper Gastrointestinal Hemorrhage, CTCAE

Clinical finding
- Finding by Cause
  - Adverse Event
    - CTCAE by Body System
      - Gastrointestinal Disorders, CTCAE
        Upper Gastrointestinal Hemorrhage, CTCAE
        Grade 4 Upper Gastrointestinal Hemorrhage, CTCAE

Recent clinical studies

Etiology

Safety and efficacy of S-1 plus oxaliplatin 130 mg/m(2) combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A).

Kashiwada T, Shinozaki K, Ueno S, Kawanaka H, Uno F, Okita Y, Fukahori M, Matsushita H, Emi Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Maehara Y, Mori M, Baba E; Kyushu Study Group of Clinical Cancer (KSCC)
Int J Clin Oncol 2021 Feb;26(2):345-354. Epub 2020 Oct 21 doi: 10.1007/s10147-020-01803-w. PMID: 33085058

Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.

Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID
Int J Radiat Oncol Biol Phys 2018 Oct 1;102(2):296-303. Epub 2018 Jun 1 doi: 10.1016/j.ijrobp.2018.05.040. PMID: 30191864

Dose-Volume Histogram Analysis of Stereotactic Body Radiotherapy Treatment of Pancreatic Cancer: A Focus on Duodenal Dose Constraints.

Goldsmith C, Price P, Cross T, Loughlin S, Cowley I, Plowman N
Semin Radiat Oncol 2016 Apr;26(2):149-56. Epub 2015 Dec 24 doi: 10.1016/j.semradonc.2015.12.002. PMID: 27000512

Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.

Chon YE, Seong J, Kim BK, Cha J, Kim SU, Park JY, Ahn SH, Han KH, Chon CY, Shin SK, Kim DY
Int J Radiat Oncol Biol Phys 2011 Dec 1;81(5):1343-51. Epub 2010 Oct 8 doi: 10.1016/j.ijrobp.2010.07.1986. PMID: 20934268

See all (4)

Diagnosis

Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114).

Heinrich K, Heinemann V, Stintzing S, Müller L, Ettrich TJ, Büchner-Steudel P, Geißler M, Trojan J, Moosmann N, Folprecht G, Schmidt J, Kanzler S, Kullmann F, Moulin JC, Werner J, Angele MK, Probst V, Held S, Schulz C, Boukovala M
Oncol Res Treat 2024;47(6):251-261. Epub 2024 Apr 2 doi: 10.1159/000538143. PMID: 38565089 Free PMC Article

Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.

See all (2)

Therapy

Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114).

Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.

Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.

Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J
Br J Cancer 2006 Aug 21;95(4):450-6. Epub 2006 Aug 1 doi: 10.1038/sj.bjc.6603267. PMID: 16880795 Free PMC Article

See all (6)